{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T07:17:37Z","timestamp":1770880657801,"version":"3.50.1"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015763","name":"Szegedi Tudom\u00e1nyegyetem","doi-asserted-by":"publisher","award":["University of Szeged Open Access Fund. Grant No.: 8282"],"award-info":[{"award-number":["University of Szeged Open Access Fund. Grant No.: 8282"]}],"id":[{"id":"10.13039\/501100015763","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015763","name":"Szegedi Tudom\u00e1nyegyetem","doi-asserted-by":"publisher","award":["Ministry of Innovation and Technology of Hungary from the National Research, Development, and Innovation Fund, financed by ITM NKFIA TKP2021-EGA-32"],"award-info":[{"award-number":["Ministry of Innovation and Technology of Hungary from the National Research, Development, and Innovation Fund, financed by ITM NKFIA TKP2021-EGA-32"]}],"id":[{"id":"10.13039\/501100015763","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cardiovascular diseases remain the leading cause of mortality in Europe, responsible for one-third of all deaths in 2021. In Hungary, the standardized death rate from cardiovascular diseases reached 722.8 per 100,000 individuals, more than double the EU average. Oral anticoagulants (OACs) play a crucial role in lowering cardiovascular mortality. The use of OACs has shifted rapidly over the past decade with the transition from vitamin K antagonists (VKAs) to direct oral anticoagulants (DOACs). Although previous studies have examined gender differences in OACs prescribing, most rely on patient-level registries and do not capture population-level exposure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To evaluate population-level trends in OACs consumption in Hungary from 2014 to 2022, stratified by age and gender, with a specific focus on detecting temporal changes in the gender gap.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>National level data were obtained from the Hungarian National Health Insurance Fund database, which includes all reimbursed prescription medications for the entire population. Utilization was measured using the WHO\u2019s ATC\/DDD methodology and expressed as defined daily doses per 1,000 inhabitants per day (DID). Linear regression was used to assess trends.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Total OACs use nearly doubled over the study period, increasing from 9.79 to 18.73 DID (Coeff. = 1.18, p &amp;lt; 0.001). VKAs use declined significantly in both genders by 41.2% in males and 47.8% in females, while DOACs use increased more than tenfold. OACs utilization was consistently higher in males. Gender differences in DOACs, initially negligible, began to widen from 2018 onward, whereas, VKAs utilization exhibited a consistently wider gender difference across all years. OACs use increased with age, peaking in the 80\u201384 age group. Apixaban became the most used OAC, reaching 6.11 DID in 2022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A marked shift from VKAs to DOACs occurred, with overall OACs use nearly doubling, with a widening gender gap in consumption of both VKAs and DOACs. Utilization was consistently higher among males and increased with age, highlighting the importance of continued monitoring to ensure effective and evidence-based anticoagulant use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1770826","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T06:51:42Z","timestamp":1770879102000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Age and gender disparities in oral anticoagulant use: a nine-year nationwide drug utilization analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Ahmed A. A.","family":"Omer","sequence":"first","affiliation":[{"name":"Institute of Clinical Pharmacy, Faculty of Pharmacy, University of Szeged","place":["Szeged, Hungary"]},{"name":"Department of Pharmacology, Faculty of Pharmacy, University of Gezira","place":["Wad Madani, Sudan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e1rta","family":"Csatordai","sequence":"additional","affiliation":[{"name":"Institute of Clinical Pharmacy, Faculty of Pharmacy, University of Szeged","place":["Szeged, Hungary"]},{"name":"Institute of Clinical Pharmacy, Albert Szent-Gy\u00f6rgyi Health Centre, University of Szeged","place":["Szeged, Hungary"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00e9ka","family":"Viola","sequence":"additional","affiliation":[{"name":"Institute of Clinical Pharmacy, Faculty of Pharmacy, University of Szeged","place":["Szeged, Hungary"]},{"name":"Institute of Clinical Pharmacy, Albert Szent-Gy\u00f6rgyi Health Centre, University of Szeged","place":["Szeged, Hungary"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e9ter","family":"Dor\u00f3","sequence":"additional","affiliation":[{"name":"Institute of Clinical Pharmacy, Faculty of Pharmacy, University of Szeged","place":["Szeged, Hungary"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e012023","DOI":"10.1161\/JAHA.119.012023","article-title":"Changes in anticoagulant utilization among United States nursing home residents with atrial fibrillation from 2011 to 2016","volume":"8","author":"Alcusky","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/ORR.S105227","article-title":"Rivaroxaban for venous thromboembolism prevention after major orthopedic surgery: translating trial data into routine clinical practice","volume":"9","author":"Beyer-Westendorf","year":"2017","journal-title":"Orthop. Res. Rev."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s40262-019-00775-z","article-title":"Apixaban: a clinical pharmacokinetic and pharmacodynamic review","volume":"58","author":"Byon","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e017559","DOI":"10.1161\/JAHA.120.017559","article-title":"Direct oral anticoagulant use: a practical guide to common clinical challenges","volume":"9","author":"Chen","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"B5","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12913-018-2874-7","article-title":"A multicenter, prospective study evaluating the impact of the clinical pharmacist-physician counselling on warfarin therapy management in Lebanon","volume":"18","author":"Choumane","year":"2018","journal-title":"BMC Health Serv. Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1111\/j.1538-7836.2010.03955.x","article-title":"Sex, age and normal post-anticoagulation D-dimer as risk factors for recurrence after idiopathic venous thromboembolism in the Prolong study extension","volume":"8","author":"Cosmi","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"B7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.amjmed.2004.01.018","article-title":"Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology","volume":"117","author":"Cushman","year":"2004","journal-title":"Am. J. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"10993","DOI":"10.3390\/ijerph182010993","article-title":"Gender and socioeconomic inequality in the prescription of direct oral anticoagulants in patients with non-valvular atrial fibrillation in primary care in catalonia (Fantas-TIC study)","volume":"18","author":"Dalmau","year":"2021","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"B9","doi-asserted-by":"publisher","first-page":"d813","DOI":"10.1136\/bmj.d813","article-title":"Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis","volume":"342","author":"Douketis","year":"2011","journal-title":"Bmj"},{"key":"B10","unstructured":"Idarucizumab \u201cPraxbind\u201d"},{"key":"B11","unstructured":"Andexanet alfa Ondexxya"},{"key":"B12","unstructured":"Causes of death - standardised death rate by NUTS 2 region of residence\n          \n          \n          2025"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1161\/STROKEAHA.118.021990","article-title":"Improved stroke prevention in atrial fibrillation after the introduction of non\u2013vitamin K antagonist oral anticoagulants: the Stockholm experience","volume":"49","author":"Forslund","year":"2018","journal-title":"Stroke"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/j.thromres.2014.09.011","article-title":"Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial","volume":"134","author":"Fuji","year":"2014","journal-title":"Thromb. Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1110036","DOI":"10.3389\/fphar.2023.1110036","article-title":"Sex and gender differences in the use of oral anticoagulants for non-valvular atrial fibrillation: a population-based cohort study in primary health care in catalonia","volume":"14","author":"Giner-Soriano","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1111\/bcp.15582","article-title":"Trends in oral anticoagulant use in patients with atrial fibrillation in Belgium from 2013 to 2019: a nationwide cohort study","volume":"89","author":"Grymonprez","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"100258","DOI":"10.1016\/j.ahjo.2023.100258","article-title":"Identifying prescribing differences of direct oral anticoagulants for atrial fibrillation within the Military Health System","volume":"26","author":"Hirschfeld","year":"2023","journal-title":"Am. Heart J. Plus Cardiol. Res. Pract."},{"key":"B18","unstructured":"Dissemination database, Statistics by subject, Population estimation\n          \n          \n          2025"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","article-title":"AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines and the heart rhythm society in collaboration with the society of thoracic surgeons","volume":"140","author":"January","year":"2019","journal-title":"Circulation"},{"key":"B20","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jjcc.2016.02.022","article-title":"Gender differences in management and clinical outcomes of atrial fibrillation patients","volume":"69","author":"Kassim","year":"2017","journal-title":"J. Cardiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1007\/s11745-005-1488-8","article-title":"Overview of hemostatic factors involved in atherosclerotic cardiovascular disease","volume":"40","author":"Kannel","year":"2005","journal-title":"Lipids"},{"key":"B22","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/S0140-6736(09)62125-5","article-title":"Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial","volume":"375","author":"Lassen","year":"","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa1006885","article-title":"Apixaban versus enoxaparin for thromboprophylaxis after hip replacement","volume":"363","author":"Lassen","year":"","journal-title":"N. Engl. J. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"519","DOI":"10.4070\/kcj.2017.0389","article-title":"Gender-related differences in management of nonvalvular atrial fibrillation in an Asian population","volume":"48","author":"Lee","year":"2018","journal-title":"Korean Circ. J."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e027211","DOI":"10.1161\/JAHA.122.027211","article-title":"Sex differences in oral anticoagulation therapy in patients hospitalized with atrial fibrillation: a nationwide cohort study","volume":"12","author":"Lee","year":"2023","journal-title":"J. Am. Heart Assoc."},{"key":"B26","doi-asserted-by":"publisher","first-page":"92","DOI":"10.26430\/CHUNGARICA.2024.54.2.92","article-title":"Az or\u00e1lis antikoagul\u00e1nsok alkalmaz\u00e1s\u00e1nak 10 \u00e9ves trendjei pitvarfibrill\u00e1ci\u00f3 miatt kat\u00e9terabl\u00e1ci\u00f3ra ker\u00fcl\\Ho betegekn\u00e9l","volume":"54","author":"Let\u00edcia","year":"2024","journal-title":"Cardiol. Hung"},{"key":"B27","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/s41569-022-00787-6","article-title":"Epidemiology and prevention of venous thromboembolism","volume":"20","author":"Lutsey","year":"2023","journal-title":"Nat. Rev. Cardiol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3390\/scipharm93030035","article-title":"Risks of oral anticoagulants: interactions with drugs and medicinal plants","volume":"93","author":"Martins","year":"2025","journal-title":"Sci. Pharm."},{"key":"B29","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.amjmed.2018.03.024","article-title":"Gender differences in antithrombotic treatment for newly diagnosed atrial fibrillation: the GLORIA-AF registry program","volume":"131","author":"Mazurek","year":"2018","journal-title":"Am. J. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12916-021-02067-5","article-title":"Prescribing of direct oral anticoagulants and warfarin to older people with atrial fibrillation in UK general practice: a cohort study","volume":"19","author":"Mitchell","year":"2021","journal-title":"BMC Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e026723","DOI":"10.1161\/JAHA.122.026723","article-title":"Trends in oral anticoagulant use among 436 864 patients with atrial fibrillation in community practice, 2011 to 2020","volume":"11","author":"Navar","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"B32","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2147\/IPRP.S458827","article-title":"Warfarin and polypharmacy challenges in Sudan: drug interactions in patient cohort","volume":"13","author":"Omer","year":"2024","journal-title":"Integr. Pharm. Res. Pract."},{"key":"B33","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.amjcard.2013.10.035","article-title":"Meta-analysis of gender differences in residual stroke risk and major bleeding in patients with nonvalvular atrial fibrillation treated with oral anticoagulants","volume":"113","author":"Pancholy","year":"2014","journal-title":"Am. J. Cardiol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.clinthera.2023.03.008","article-title":"Mortality on DOACs versus on vitamin K antagonists in atrial fibrillation: analysis of the Hungarian Health Insurance Fund database","volume":"45","author":"Papp","year":"2023","journal-title":"Clin. Ther."},{"key":"B35","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1160\/TH08-10-0635","article-title":"Gender differences in stroke risk of atrial fibrillation patients on oral anticoagulant treatment","volume":"101","author":"Poli","year":"2009","journal-title":"Thromb. Haemost."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1111\/jth.13116","article-title":"Sex difference in the risk of recurrent venous thrombosis: a detailed analysis in four European cohorts","volume":"13","author":"Roach","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.3390\/medicina61081354","article-title":"Malnutrition and frailty as independent predictors of adverse outcomes in hospitalized older adults: a prospective single center study","volume":"61","author":"Sad\u0131\u00e7","year":"2025","journal-title":"Med. Mex."},{"key":"B38","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s11239-016-1380-1","article-title":"Age-dependency of prescribing patterns of oral anticoagulant drugs in Austria during 2011\u20132014","volume":"42","author":"Schuh","year":"2016","journal-title":"J. Thromb. Thrombolysis"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur. Heart J."},{"key":"B40","first-page":"2744","article-title":"Management of venous and arterial thrombosis","volume-title":"J. Clin. Med.","author":"Stan\u010diakov\u00e1","year":"2024"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1161\/STROKEAHA.118.023959","article-title":"Disparities and temporal trends in the use of anticoagulation in patients with ischemic stroke and atrial fibrillation","volume":"50","author":"Sur","year":"2019","journal-title":"Stroke"},{"key":"B42","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/bcp.14404","article-title":"Warfarin and food, herbal or dietary supplement interactions: a systematic review","volume":"87","author":"Tan","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"e14107","DOI":"10.1111\/eci.14107","article-title":"Temporal trends of gender disparities in oral anticoagulant use in patients with atrial fibrillation","volume":"54","author":"Teppo","year":"2024","journal-title":"Eur. J. Clin. Invest"},{"key":"B44","unstructured":"The Danish health data authority\n          \n          \n          2025"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e005801","DOI":"10.1161\/JAHA.117.005801","article-title":"Sex differences in the use of oral anticoagulants for atrial fibrillation: a report from the National Cardiovascular Data Registry (NCDR\u00ae) PINNACLE Registry","volume":"6","author":"Thompson","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1016\/S0140-6736(09)60734-0","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial","volume":"373","author":"Turpie","year":"2009","journal-title":"Lancet"},{"key":"B47","year":"2025","journal-title":"Idarucizumab"},{"key":"B48","doi-asserted-by":"publisher","first-page":"9538","DOI":"10.3390\/nu7115479","article-title":"New insights into the pros and cons of the clinical use of vitamin K antagonists (VKAs) versus direct oral anticoagulants (DOACs)","volume":"7","author":"Van Gorp","year":"2015","journal-title":"Nutrients"},{"key":"B49","doi-asserted-by":"publisher","first-page":"6707985","DOI":"10.1155\/2022\/6707985","article-title":"Time trends and treatment pathways in prescribing individual oral anticoagulants in patients with nonvalvular atrial fibrillation: an observational study of more than three million patients from Europe and the United States","volume":"2022","author":"Vora","year":"2022","journal-title":"Int. J. Clin. Pract."},{"key":"B50","doi-asserted-by":"publisher","first-page":"I\u20134","DOI":"10.1161\/01.CIR.0000078468.11849.66","article-title":"The epidemiology of venous thromboembolism","volume":"107","author":"White","year":"2003","journal-title":"Circulation"},{"key":"B51","unstructured":"Guidelines for ATC classification and DDD assignment\n          \n          \n          2024"},{"key":"B52","volume-title":"Introduction to drug utilization research","year":"2003"},{"key":"B53","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s12877-022-02965-0","article-title":"Barriers to prescribing oral anticoagulants to inpatients aged 80 years and older with nonvalvular atrial fibrillation: a cross-sectional study","volume":"22","author":"Xia","year":"2022","journal-title":"BMC Geriatr."},{"key":"B54","doi-asserted-by":"publisher","first-page":"e015689","DOI":"10.1161\/JAHA.120.015689","article-title":"Sex differences in oral anticoagulation and outcomes of stroke and intracranial bleeding in newly diagnosed atrial fibrillation","volume":"9","author":"Yong","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"B55","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1002\/phar.2158","article-title":"Trends and variation in oral anticoagulant choice in patients with atrial fibrillation, 2010\u20132017","volume":"38","author":"Zhu","year":"2018","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1770826\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T06:51:44Z","timestamp":1770879104000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1770826\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":55,"alternative-id":["10.3389\/fphar.2026.1770826"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1770826","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"article-number":"1770826"}}